美国食品药物管理局(FDA)核准hydrocortisone加acyclovir的复方药膏(商品名LipsovirMedivir AB公司)用於治疗復发的唇疱疹—单纯疱疹，以降低溃疡性单纯疱疹可能性，缩短病灶癒合时间。

此项治疗被核准用於成人和12岁以上小孩。
      　　
此项核准是根据第3期临床计画的资料，显示使用 hydrocortisone加acyclovir复方药膏的病患，42%未发生有水泡、溃疡和硬皮的单纯疱疹，使用安慰剂的病患只有26%达到。
      　　
对於那些发生单纯疱疹的病患，治癒时间显著缩短，比接受安慰剂组减少了1.5天。
      　　
药厂在新闻稿中指出，目前市面上治疗单纯疱疹的药膏都没有前述作用，也未显示及早治疗可以预防发作。
      
FDA Approves Hydrocortisone/Acyclovir Cream for Treating Cold Sores The US Food and Drug Administration (FDA) has approved a hydrocortisone plus acyclovir cream (Lipsovir, Medivir AB) for the early treatment of recurrent herpes labialis — cold sores — to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time. Treatment is approved for adults and children aged 12 years and older.
The approval was based on data from a clinical phase 3 program showing that 42% of patients using hydrocortisone/acyclovir cream did not develop cold sores with blisters, ulcers, and crusting compared with 26% of those receiving placebo.
For those patients who developed cold sores, healing time was significantly decreased, being lowered by 1.5 days in the active treatment group vs in the placebo group."No product currently marketed for the treatment of coldsoreshasacorresponding label or has been shown to prevent an outbreak with early treatment," the company noted in a news release.